The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Day One Biopharmaceuticals Inc’s stock clocked out at $6.82, up 0.15% from its previous closing price of $6.81. In other words, the price has increased by $0.15 from its previous closing price. On the day, 1.76 million shares were traded. DAWN stock price reached its highest trading level at $7.115 during the session, while it also had its lowest trading level at $6.745.
Ratios:
To gain a deeper understanding of DAWN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.65. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On October 09, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $32 to $33.
BofA Securities Upgraded its Underperform to Buy on August 01, 2024, whereas the target price for the stock was revised from $11 to $24.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when York Charles N II sold 4,106 shares for $6.77 per share. The transaction valued at 27,786 led to the insider holds 278,000 shares of the business.
Dubow Adam sold 4,365 shares of DAWN for $29,538 on Aug 18 ’25. The Gen Counsel & Secretary now owns 54,858 shares after completing the transaction at $6.77 per share. On Aug 18 ’25, another insider, Bender Jeremy, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 16,058 shares for $6.77 each. As a result, the insider received 108,666 and left with 161,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 698586240 and an Enterprise Value of 248485776. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.72 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at 1.324 whereas that against EBITDA is -2.284.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.26, which has changed by -0.5197183 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $16.76, while it has fallen to a 52-week low of $5.64. The 50-Day Moving Average of the stock is 2.91%, while the 200-Day Moving Average is calculated to be -28.05%.
Shares Statistics:
It appears that DAWN traded 1.58M shares on average per day over the past three months and 2605960 shares per day over the past ten days. A total of 102.43M shares are outstanding, with a floating share count of 74.68M. Insiders hold about 27.09% of the company’s shares, while institutions hold 74.52% stake in the company. Shares short for DAWN as of 1753920000 were 9907747 with a Short Ratio of 6.28, compared to 1751241600 on 11693232. Therefore, it implies a Short% of Shares Outstanding of 9907747 and a Short% of Float of 14.32.
Earnings Estimates
A detailed examination of Day One Biopharmaceuticals Inc (DAWN) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.18 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$0.8 and -$1.35 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$0.83, with 8.0 analysts recommending between -$0.4 and -$1.42.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $38.2M. It ranges from a high estimate of $41M to a low estimate of $36.75M. As of the current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $93.76MFor the next quarter, 9 analysts are estimating revenue of $41.98M. There is a high estimate of $47M for the next quarter, whereas the lowest estimate is $37.9M.
A total of 10 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151M, while the lowest revenue estimate was $139.32M, resulting in an average revenue estimate of $144.91M. In the same quarter a year ago, actual revenue was $131.16MBased on 10 analysts’ estimates, the company’s revenue will be $215.17M in the next fiscal year. The high estimate is $295M and the low estimate is $171.12M.
